Literature DB >> 20211692

Mechanism of immunopotentiation by aluminum-containing adjuvants elucidated by the relationship between antigen retention at the inoculation site and the immune response.

Stephanie M Noe1, Mark A Green, Harm HogenEsch, Stanley L Hem.   

Abstract

The relationship between depot formation and immunopotentiation was studied by comparing the retention of antigen at the inoculation site with antibody production in rats. A model (111)In-labeled alpha casein (IDCAS) antigen was formulated into four vaccines: IDCAS adsorbed onto either aluminum hydroxide adjuvant (AH) or aluminum phosphate adjuvant (AP); non-adsorbed IDCAS with phosphate-treated AP (PTAP); and IDCAS solution. Gamma scintigraphy showed the order of retention following subcutaneous administration to be: AH adsorbed>AP adsorbed>non-adsorbed with PTAP=solution. The antibody titers followed the order: non-adsorbed with PTAP=AP adsorbed>AH adsorbed>>solution. The presence of an aluminum-containing adjuvant was essential for immunopotentiation, but retention of the antigen at the inoculation site was not required. (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20211692     DOI: 10.1016/j.vaccine.2010.02.085

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  29 in total

1.  Antibodies elicited by yeast glycoproteins recognize HIV-1 virions and potently neutralize virions with high mannose N-glycans.

Authors:  Hong Zhang; Hu Fu; Robert J Luallen; Bingfen Liu; Fang-Hua Lee; Robert W Doms; Yu Geng
Journal:  Vaccine       Date:  2015-08-13       Impact factor: 3.641

Review 2.  Conjugate Vaccine Immunotherapy for Substance Use Disorder.

Authors:  Paul T Bremer; Kim D Janda
Journal:  Pharmacol Rev       Date:  2017-07       Impact factor: 25.468

Review 3.  Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts.

Authors:  Calvin C Willhite; Nataliya A Karyakina; Robert A Yokel; Nagarajkumar Yenugadhati; Thomas M Wisniewski; Ian M F Arnold; Franco Momoli; Daniel Krewski
Journal:  Crit Rev Toxicol       Date:  2014-10       Impact factor: 5.635

4.  Working together: interactions between vaccine antigens and adjuvants.

Authors:  Christopher B Fox; Ryan M Kramer; Lucien Barnes V; Quinton M Dowling; Thomas S Vedvick
Journal:  Ther Adv Vaccines       Date:  2013-05

5.  Enhancing Efficacy and Stability of an Antiheroin Vaccine: Examination of Antinociception, Opioid Binding Profile, and Lethality.

Authors:  Candy S Hwang; Paul T Bremer; Cody J Wenthur; Sam On Ho; SuMing Chiang; Beverly Ellis; Bin Zhou; Gary Fujii; Kim D Janda
Journal:  Mol Pharm       Date:  2018-02-19       Impact factor: 4.939

Review 6.  Beyond antigens and adjuvants: formulating future vaccines.

Authors:  Tyson J Moyer; Andrew C Zmolek; Darrell J Irvine
Journal:  J Clin Invest       Date:  2016-03-01       Impact factor: 14.808

7.  Safety and efficiency of active immunization with detoxified antigen against scorpion venom: side effect evaluation.

Authors:  Nassrine Bachsais; Lila Boussag-Abib; Fatima Laraba-Djebari
Journal:  Inflamm Res       Date:  2017-05-17       Impact factor: 4.575

8.  A nanoparticle-based nicotine vaccine and the influence of particle size on its immunogenicity and efficacy.

Authors:  Zongmin Zhao; Yun Hu; Reece Hoerle; Meaghan Devine; Michael Raleigh; Paul Pentel; Chenming Zhang
Journal:  Nanomedicine       Date:  2016-08-09       Impact factor: 5.307

Review 9.  A case-study investigating the physicochemical characteristics that dictate the function of a liposomal adjuvant.

Authors:  Yvonne Perrie; Elisabeth Kastner; Randip Kaur; Alexander Wilkinson; Andrew J Ingham
Journal:  Hum Vaccin Immunother       Date:  2013-04-12       Impact factor: 3.452

10.  Adsorption of recombinant poxvirus L1-protein to aluminum hydroxide/CpG vaccine adjuvants enhances immune responses and protection of mice from vaccinia virus challenge.

Authors:  Yuhong Xiao; Yuhong Zeng; Edward Alexander; Shyam Mehta; Sangeeta B Joshi; George W Buchman; David B Volkin; C Russell Middaugh; Stuart N Isaacs
Journal:  Vaccine       Date:  2012-11-12       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.